The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A modular, open-label, phase I/IIa study to evaluate the safety, tolerability, pharmacokinetics (PKs) and anti-tumour activity of a first-in-class (FIC) specific dUTPase inhibitor CV6-168 combined with anti-cancer treatments in patients (pts) with advanced malignancies.
 
Victoria Coyle
Honoraria - Gilead Sciences (I)
Consulting or Advisory Role - Merck
Speakers' Bureau - SERVIER
Research Funding - Astex Pharmaceuticals (Inst); Bayer (Inst); CellCentric (Inst)
Travel, Accommodations, Expenses - SERVIER
 
Elizabeth Ruth Plummer
Honoraria - Amgen (I); AstraZeneca/MedImmune; Bristol-Myers Squibb; Novartis Pharmaceuticals UK Ltd.; Pfizer (I); Tesaro
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Benevolent AI; Biosceptre; Bristol-Myers Squibb/Medarex; CV6 Therapeutics; Cybrexa Therapeutics; Ellipses Pharma; Genmab; Immunocore; Incyte; Medivir; Nerviano Medical Sciences; Novartis; Novartis; Onxeo; Pierre Fabre; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
Other Relationship - Alligator Bioscience; AstraZeneca; GlaxoSmithKline; Sotio
 
Udai Banerji
Employment - Institute of Cancer Research
Consulting or Advisory Role - Carrick Therapeutics; Ellipses Pharma; PEGASCY; PharmEnable
Research Funding - Avacta Life Sciences (Inst); BTG (Inst); Carrick Therapeutics (Inst); Chugai Pharma (Inst); Verastem (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Bayer; Sierra Oncology
 
T.R. Jeffry Evans
Honoraria - Ascelia (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol Myers Squibb (Inst); CV6 Therapeutics (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); Seagen (Inst)
Consulting or Advisory Role - Karus Therapeutics (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Ewopharma (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); United Medical (Inst)
Research Funding - Adaptimmune (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Avacta Life Sciences (Inst); Basilea (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Codiak BioSciences (Inst); CV6 Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Exscientia (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOnctura (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Moderna Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Nurix (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Sierra Pharma (Inst); Starpharma (Inst); T3 Pharmaceuticals (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - iOnctura (Inst); Medivir (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre
Other Relationship - Genmab (Inst)
 
Glen Clack
Employment - Carrick Therapeutics; Evgen
Stock and Other Ownership Interests - Carrick Therapeutics
Consulting or Advisory Role - Breakpoint Therapeutics; Cumulus Oncology; CV6 Therapeutics; Galytx; Gray Wolf Therapeutics; Invox; ITeos Therapeutics; Nadeno Nanoscience; Neophore Therapeutics; Nouscom; Phion Therapeutics
 
Karl A Mulligan
Employment - CV6 Therapeutics NI) Ltd
Leadership - CV6 Therapeutics NI) Ltd
Stock and Other Ownership Interests - CV6 Therapeutics NI) Ltd
Research Funding - CV6 Therapeutics NI) Ltd
Patents, Royalties, Other Intellectual Property - CV6 Therapeutics NI) Ltd
 
Peter M. Wilson
Employment - CV6 Therapeutics NI) Ltd
Stock and Other Ownership Interests - CV6 Therapeutics NI) Ltd
Research Funding - CV6 Therapeutics NI) Ltd
Patents, Royalties, Other Intellectual Property - CV6 Therapeutics NI) Ltd
 
Tess Barker
Employment - CV6 Therapeutics NI) Ltd
Stock and Other Ownership Interests - CV6 Therapeutics NI) Ltd
Consulting or Advisory Role - CV6 Therapeutics NI) Ltd
 
Melissa LaBonte Wilson
Employment - CV6 Therapeutics NI Ltd (I)
Stock and Other Ownership Interests - CV6 Therapeutics NI Ltd; CV6 Therapeutics NI Ltd (I)
Consulting or Advisory Role - CV6 Therapeutics NI Ltd
Research Funding - AstraZeneca; CV6 Therapeutics NI Ltd; CV6 Therapeutics NI Ltd (I)
Patents, Royalties, Other Intellectual Property - CV6 Therapeutics NI Ltd; CV6 Therapeutics NI Ltd (I)
 
Robert D. Ladner
Employment - CV6 Therapeutics NI) Ltd
Leadership - CV6 Therapeutics NI) Ltd
Stock and Other Ownership Interests - CV6 Therapeutics NI) Ltd
Research Funding - CV6 Therapeutics NI) Ltd
Patents, Royalties, Other Intellectual Property - CV6 Therapeutics NI) Ltd
 
Richard H. Wilson
Honoraria - SERVIER
Consulting or Advisory Role - Alcimed; Amgen; Amphista Therapeutics (Inst); Bayer; Boehringer Ingelheim; CV6 Therapeutics; Nucana (Inst); Pierre Fabre; RIN Institute
Travel, Accommodations, Expenses - Amgen; Merck KGaA; NuCana; Pierre Fabre; Takeda